Noh

Theravance Biopharma to Present New Ampreloxetine Data at the 34th International Symposium on The Autonomic Nervous System

Retrieved on: 
Thursday, November 16, 2023
SEQUOIA, American Autonomic Society, Autonomic nervous system, OHQ, Orthostatic hypotension, AAS, Patient, University School, Research, Week, Noh, Neurology, Dysautonomia, Pharmaceutical industry, Medical imaging

DUBLIN, Nov. 16, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that a new, anchor-based analysis of ampreloxetine data in neurogenic orthostatic hypotension (nOH) will be presented at the 34th International Symposium on The Autonomic Nervous System, a meeting of the American Autonomic Society (AAS), taking place November 15-18, 2023, in Rio Grande, Puerto Rico.

Key Points: 
  • DUBLIN, Nov. 16, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that a new, anchor-based analysis of ampreloxetine data in neurogenic orthostatic hypotension (nOH) will be presented at the 34th International Symposium on The Autonomic Nervous System, a meeting of the American Autonomic Society (AAS), taking place November 15-18, 2023, in Rio Grande, Puerto Rico.
  • Anchor-based analyses help establish thresholds used to interpret the clinical meaningfulness of changes in patient-reported outcomes measures such as the Orthostatic Hypotension Questionnaire (OHQ).
  • This anchor-based analysis model will aid in the interpretation of clinically meaningful changes to the OHSA composite score observed in CYPRESS.
  • Further, establishment of an anchor-based, clinically meaningful change in the OHSA composite primary endpoint will be important for clinicians, regulators, and payors.

University of Phoenix College of Nursing Student and Graduate Honored with Nurse of the Year Award from Community Health System

Retrieved on: 
Wednesday, September 20, 2023
Nursing, Education, Health, Hospitals, Continuing, University, Training, Learning, Bachelor of Science in Nursing, College, Arizona State University Downtown Phoenix campus, Culture, Professional, COVID-19, Thorn, University of Phoenix, Nurse education, Student, Community, Patient, Australian Nurse of the Year, CHS, Noh, RN, Faculty, HEU, Phoenix College, Safety, Community Health Systems, CEP, Science

University of Phoenix celebrates College of Nursing student Nou Heu and College of Nursing graduate Susan Thorn, on receiving Nurse of the Year awards from the Association for California Nursing Leaders’ San Joaquin Valley Chapter.

Key Points: 
  • University of Phoenix celebrates College of Nursing student Nou Heu and College of Nursing graduate Susan Thorn, on receiving Nurse of the Year awards from the Association for California Nursing Leaders’ San Joaquin Valley Chapter.
  • Both nurses work for Community Health System, a leading healthcare organization committed to delivering high-quality care to communities in central California.
  • “I am incredibly honored and grateful to receive the Nurse of the Year award,” shares Thorn.
  • The University of Phoenix College of Nursing recognizes that flexible and relevant educational programs are essential to prepare students for contemporary nursing practice.

GetYourGuide Unlocks Four New 'Originals by GetYourGuide' Experiences That Immerse Travelers in the Unique Cultural Traditions of Kyoto City

Retrieved on: 
Monday, July 10, 2023
UNESCO, Zen, Dance, Music, Partnership, Travel, Singing, Noh, World Heritage Site, Geisha, Culture, GetYourGuide, Ninna-ji, History, Mask, City, Meditation, Female, Teahouse, Tourism

"Many of Japan's culturally significant sites are hard to access — or even off-limits to visitors — until now.

Key Points: 
  • "Many of Japan's culturally significant sites are hard to access — or even off-limits to visitors — until now.
  • Our newest Originals by GetYourGuide will help travelers discover Kyoto's sacred traditions and rich culture through immersive experiences that take them off the beaten path."
  • In this once-in-a-lifetime experience, travelers will unlock the gates to the Ninna-Ji's imperial and spiritual history before it opens to the public.
  • To learn more about upcoming Originals by GetYourGuide and discover other unforgettable experiences around the world, please visit www.getyourguide.com .

Malta Announces Addition of Storage Industry Veteran Jin Noh to Direct Business Development & Policy

Retrieved on: 
Tuesday, May 23, 2023
Other Energy, Utilities, Oil, Gas, Environment, Coal, Alternative Energy, Energy, Green Technology, U.S. Department of Energy, Office of Inspector General, Duke University, Business development, Interim, Inc., New York State Energy Research and Development Authority, California Energy Commission, Noh, University, National Integration Council, U.S. Department of Defense Strategy for Operating in Cyberspace, Public policy, CESA, Berkeley, Original equipment manufacturer, Policy, DOE, Energy policy, Development, NYSERDA, CEC, Economics, Renewable energy

Malta Inc., a pioneer in long-duration energy storage (LDES) that offers utility-scale clean energy replacements for coal, oil, and gas power plants, announced today the addition of Jin Noh as Director, Business Development & Policy.

Key Points: 
  • Malta Inc., a pioneer in long-duration energy storage (LDES) that offers utility-scale clean energy replacements for coal, oil, and gas power plants, announced today the addition of Jin Noh as Director, Business Development & Policy.
  • Noh joins Malta with 10 years of policy and analyst experience in the utility, regulatory, and technology industries, including prior work with energy storage advocacy and consulting groups.
  • Noh most recently served as Interim Executive Director and Policy Director at the California Energy Storage Alliance (CESA).
  • Noh holds a Master of Public Policy with a focus on Energy Policy from the University of California, Berkeley and a bachelor’s degree in public policy studies and economics from Duke University.

Theravance Biopharma, Inc. Announces Orphan Drug Designation Granted to Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy

Retrieved on: 
Tuesday, May 9, 2023
Blood pressure, Orphan Drug Act of 1983, US Foods, Noh, Prevalence, Marketing, ODD, Quality of life, Multiple system atrophy, Head, Movement, Orthostatic hypotension, Muscle weakness, ODA, Orphan drug, Dizziness, Patient, MSA, Norepinephrine, Dysautonomia, Orphan, Heart rate, FDA, Food, Caregiver, Fatigue, Pharmaceutical industry

DUBLIN, May 9, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) status to ampreloxetine for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA).

Key Points: 
  • DUBLIN, May 9, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) status to ampreloxetine for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA).
  • MSA is a rare neurodegenerative disorder in which patients suffer autonomic dysfunction affecting movement, balance, heart rate and blood pressure.
  • "We are very pleased to have received Orphan Drug status for ampreloxetine in the treatment of nOH in patients with MSA," said Rick E Winningham, Chief Executive Officer.
  • "Ampreloxetine has the potential to improve MSA patients' and their caregivers' quality of life significantly.

Theravance Biopharma, Inc. Announces Strategic Actions and Reports Fourth Quarter / Full Year 2022 Financial Results and Business Update

Retrieved on: 
Monday, February 27, 2023
Janus, Orthostatic hypotension, Chronic obstructive pulmonary disease, Blood pressure, JAK, Telephone, Atrophy, Norepinephrine, SG, American Autonomic Society, GSK, Internet, MBA, Research, Noh, Owens & Minor, Executive, Maintenance, J.P. Morgan & Co., Partnership, Webcast, FDA, Patient, R, MSA, Janssen, Growth, Research and development, Wesleyan University, COPD, Bank statement, CIBC, CIBC World Markets, Columbia University, Hypertension, Asthma, Sale, BA, Merrill (company), Multiple system atrophy, Medication, Administration, Pharmaceutical industry, Cryptocurrency, Beauty salon, Holding company, Fine chemical, Management, Viatris

Revenue: Total revenue for the fourth quarter of 2022 was $14.6 million, almost entirely comprised of $14.6 million in Viatris collaboration revenue.

Key Points: 
  • Revenue: Total revenue for the fourth quarter of 2022 was $14.6 million, almost entirely comprised of $14.6 million in Viatris collaboration revenue.
  • In the fourth quarter of 2022, Theravance Biopharma recognized its first revenue associated with non-US YUPELRI royalties.
  • Cash burn in fourth quarter of 2022 was $7 million excluding a $118 million tax payment and $34 million of share repurchases.
  • A replay of the webcast will be available on Theravance Biopharma's website for 30 days through March 29, 2023.

Ampreloxetine Data in Neurogenic Orthostatic Hypotension to be Presented at the 33rd International Symposium on the Autonomic Nervous System

Retrieved on: 
Wednesday, November 2, 2022
American Autonomic Society, AAS, Center, Clinical trial, Parkinson's disease, Autonomic nervous system, Biopharma LLC, NASDAQ, Company, Pure autonomic failure, Autonomic, Patient, Multiple system atrophy, Noh, International Symposium on Endovascular Therapy, 2021 Essex County Council election, Drug development, Bachelor of Medicine, Bachelor of Surgery, LS, Quality of life, Beth Israel Deaconess Medical Center, Orthostatic hypotension, MSA, Caregiver burden, Pharmaceutical industry, Hydraulic machinery, Neurology

DUBLIN, Nov. 2, 2022 /PRNewswire/ -- Theravance Biopharma, Inc.("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today will present new ampreloxetine data in neurogenic orthostatic hypotension (nOH) from the Company's Phase 3 program at the 33rd International Symposium on the Autonomic Nervous System, a meeting of the American Autonomic Society (AAS).

Key Points: 
  • DUBLIN, Nov. 2, 2022 /PRNewswire/ -- Theravance Biopharma, Inc.("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today will present new ampreloxetine data in neurogenic orthostatic hypotension (nOH) from the Company's Phase 3 program at the 33rd International Symposium on the Autonomic Nervous System, a meeting of the American Autonomic Society (AAS).
  • Ampreloxetine is an investigational, once-daily norepinephrine reuptake inhibitor in development for the treatment of symptomatic nOH in patients with multiple system atrophy (MSA).
  • "These ampreloxetine data are encouraging for patients with MSA suffering with neurogenic orthostatic hypotension.
  • MSA is a progressive brain disorder that affects movement and balance and disrupts the function of the autonomic nervous system.

Dermafirm x Oracle Medical Group, Signed a joint research and development business agreement for medical cosmetics

Retrieved on: 
Thursday, October 6, 2022
National Association Medical Staff Services, MOU, Dermatology, Multimedia, Technology, Oracle Collaboration Suite, CEO, Noh, Skin, Cosmetics, Pharmaceutical industry, Medical device, Oracle

SEOUL, South Korea, Oct. 6, 2022 /PRNewswire/ -- Dermafirm, Global Derma Cosmetics Company (CEO : Han Yoon-Jae) signed a working agreement (MOU) with Oracle Medical Group (Noh Young-woo) for joint research and development of medical cosmetics at Dermafirm's headquarter located in Gangnam-gu, Seoul, on 29 October.

Key Points: 
  • SEOUL, South Korea, Oct. 6, 2022 /PRNewswire/ -- Dermafirm, Global Derma Cosmetics Company (CEO : Han Yoon-Jae) signed a working agreement (MOU) with Oracle Medical Group (Noh Young-woo) for joint research and development of medical cosmetics at Dermafirm's headquarter located in Gangnam-gu, Seoul, on 29 October.
  • Oracle Medical Group, which has signed a joint development agreement with Dermafirm, is a global medical group with unrivaled dermatology channels in Korea, overseas networks, skin clinical data and know-how.
  • Following the signing of the agreement, the two companies will jointly develop medical cosmetics based on Dermafirm's cosmetic materials and formulation R&D capabilities and Oracle Medical Group's extensive know-how and experience in skin clinical.
  • Oracle President Noh Young-woo said, "Based on Oracle Medical Group's experience in dermatology and plastic surgery, we are excited to be able to work together on the development of cosmetics with Dermafirm, the leading brand of Derma Cosmetics."

Theravance Biopharma to Sell TRELEGY ELLIPTA Royalty Interests to Royalty Pharma for Approximately $1.1 Billion in Upfront Cash with Over $1.5 Billion in Potential Total Value

Retrieved on: 
Wednesday, July 13, 2022
Slate, 808, Consensus, Regulation of tobacco by the U.S. Food and Drug Administration, Skadden, WHEN, Tax, LLC, Tender, TIME, COPD, Patient, Internet, Investor, Food, Private Securities Litigation Reform Act, Securities Exchange Act of 1934, IT, Achievement, SEC, Marketing, Pharma, Management, Company, Decision-making, NPV, Orthostatic hypotension, Goal, GSK, Noh, IST, Type, SEC filing, MSA, COVID-19, European Medicines Agency, Therapy, Failure, FDA, NDA, Growth, Industry, Telephone, Chronic obstructive pulmonary disease, NASDAQ, Debt-to-GDP ratio, Maintenance, Name, ARE, Trial of the century, Asthma, Royalty Pharma, Note, Pharmaceutical industry, Security (finance), Bank

At the completion of this process, Theravance Biopharma expects to be well-capitalized with a streamlined and debt-free balance sheet.

Key Points: 
  • At the completion of this process, Theravance Biopharma expects to be well-capitalized with a streamlined and debt-free balance sheet.
  • In addition, Royalty Pharma's investment in ampreloxetine validates its potential as a therapy to manage symptomatic neurogenic orthostatic hypotension (nOH) in MSA patients.
  • Royalty Pharma's $40 million investment in ampreloxetine includes a $25 million upfront payment and an additional $15 millionpayment upon the first regulatory approval of ampreloxetine2.
  • "Royalty Pharma is an industry leader in identifying world class therapeutics and structuring creative financing transactions that support innovative biopharma companies holding royalty interests.

Theravance Biopharma to Sell TRELEGY ELLIPTA Royalty Interests to Royalty Pharma for Approximately $1.1 Billion in Upfront Cash with Over $1.5 Billion in Potential Total Value

Retrieved on: 
Wednesday, July 13, 2022
Slate, 808, Consensus, Regulation of tobacco by the U.S. Food and Drug Administration, Skadden, WHEN, Tax, LLC, Tender, TIME, COPD, Patient, Internet, Investor, Food, Private Securities Litigation Reform Act, Securities Exchange Act of 1934, IT, Achievement, SEC, Marketing, Pharma, Management, Company, Decision-making, NPV, Orthostatic hypotension, Goal, GSK, Noh, IST, Type, SEC filing, MSA, COVID-19, European Medicines Agency, Therapy, Failure, FDA, NDA, Growth, Industry, Telephone, Chronic obstructive pulmonary disease, NASDAQ, Multimedia, Debt-to-GDP ratio, Maintenance, Name, ARE, Trial of the century, Asthma, Royalty Pharma, Note, Pharmaceutical industry, Security (finance), Bank

At the completion of this process, Theravance Biopharma expects to be well-capitalized with a streamlined and debt-free balance sheet.

Key Points: 
  • At the completion of this process, Theravance Biopharma expects to be well-capitalized with a streamlined and debt-free balance sheet.
  • In addition, Royalty Pharma's investment in ampreloxetine validates its potential as a therapy to manage symptomatic neurogenic orthostatic hypotension (nOH) in MSA patients.
  • Royalty Pharma's $40 million investment in ampreloxetine includes a $25 million upfront payment and an additional $15 millionpayment upon the first regulatory approval of ampreloxetine2.
  • "Royalty Pharma is an industry leader in identifying world class therapeutics and structuring creative financing transactions that support innovative biopharma companies holding royalty interests.